News

Selinexor Receives FDA Fast Track Designation for Patients with Penta-Refractory Myeloma
April 12, 2018 11:30 am
The U.S. Food and Drug Administration (FDA) this week granted Fast Track designation to Karyopharm’s selinexor, an oral Selective Inhibitor of Nuclear Export (SINE) compound for the treatment of myeloma patients who have received at least three...
Read More
Staten Island Myeloma Support Group Hosts 9/11 Health and Compensation Presentation
March 29, 2018 11:15 am
Read More
On Being a Myeloma Warrior
March 23, 2018 10:30 am
Read More
AbbVie and IMF Announce Partnership to Study the Role of a Genetic Mutation in Outcomes of Patients with Multiple Myeloma
March 23, 2018 10:30 am
Read More

Pages